Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Aligos Therapeutics ( (ALGS) ) has provided an announcement.
On February 11, 2025, Aligos Therapeutics entered into a Securities Purchase Agreement with investors for a private placement, expected to result in approximately $105 million in gross proceeds. This funding is anticipated to support the advancement of their ALG-000184 into a Phase 2 clinical study and extend the company’s cash runway into the second half of 2026. The private placement, led by a life sciences investment firm, involves the sale of common stock and warrants and is expected to close on February 13, 2025. This financial boost is a strategic move to solidify Aligos’s position in the biotechnology industry focused on liver and viral diseases, providing potential long-term benefits for stakeholders.
More about Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver and viral diseases, including chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, and coronaviruses.
YTD Price Performance: -34.66%
Average Trading Volume: 416,981
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $99.38M
Learn more about ALGS stock on TipRanks’ Stock Analysis page.
